e-1635 (Health care services)
Original language of petition: English
Petition to the Government of Canada
- 15 other countries, including the United States, France, Germany, Sweden and Italy, have already approved Spinraza as a treatment for patients with Spinal Muscular Atrophy (SMA);
- Health Canada has already approved Spinraza for the treatment of SMA;
- Through clinical evidence, Spinraza has shown to reduce the risk of death and improve motor and respiratory functions;
- Long-term monetary and social costs to the provinces without the use of Spinraza will be higher due to eventual invasive and costly procedures that otherwise could potentially be avoided;
- Treatment of SMA of any type should be started as early as possible to prevent disease progression and ultimately save life as well as improve quality of life.
- Open for signature
- April 23, 2018, at 4:44 p.m. (EDT)
- Closed for signature
- August 21, 2018, at 4:44 p.m. (EDT)
- Presented to the House of Commons
-
Tom Kmiec
(Calgary Shepard)
October 17, 2018 (Petition No. 421-02756) - Government response tabled
- November 28, 2018